logo-loader

Kazia Therapeutics directors buy more shares through on-market trades

Published: 14:29 24 Feb 2020 AEDT

Kazia Therapeutics Ltd - Kazia Therapeutics directors buy more shares through on-market trades
The clinical trial results translated into a material re-rating of the company’s valuation.

Kazia Therapeutics Ltd (ASX:KZA) CEO Dr James Garner and director Steven Coffey have increased their shareholding in the company by purchasing shares on market.

Dr Garner acquired 15,000 shares and Coffey bought 10,000 shares to increase their holdings to 200,000 and 251,474 respectively.

Initial success for key R&D programs

Kazia had a transformational year in 2019 with initial clinical efficacy read-outs from both its key R&D programs.

This included initial data from the ongoing phase 2 clinical trial of GDC-0084 (paxalisib) in glioblastoma which showed concrete signals of clinical efficacy.

2019 was also a positive year for the Cantrixil program, with positive data reported from the ongoing phase I study in ovarian cancer

These clinical trial results translated into a material re-rating of the company’s valuation.

On January 1 2019 Kazia shares traded at 34 cents. On December 31 2019 they traded at 60 cents.

OzAurum to start drilling at Boca Rica Lithium Project

OzAurum Resources Ltd (ASX:OZM) CEO and managing director Andrew Pumphrey sits down with Proactive’s Jonathan Jackson to discuss an upcoming drilling program at Boca Rica Lithium Project in Brazil, following the identification of a spodumene zone. The company plans to start drilling in the next...

2 hours, 10 minutes ago